Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,859 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05911217RecruitingPhase 1
CT041 treatment after chemotherapy for resected pancreatic cancer
This Phase 1 study tests whether CT041 is safe and may help prevent pancreatic cancer from coming back after it’s been removed and you’ve completed standard chemotherapy. You may be eligible if your tumor is positive for CLDN18.2 and your recovery and blood tests meet key requirements.
Beijing, Beijing MunicipalityAges 18–79 - NCT05913388RecruitingPhase 2
Testing a new drug plus pembrolizumab versus pembrolizumab alone
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Portland, OregonAges 18 years+ - NCT05916040Recruiting
MRI-guided treatment for locally advanced rectal cancer
This trial studies a total “before-surgery” treatment plan for locally advanced rectal cancer, using MRI (a detailed scan) to help guide radiation. It may help patients by aiming to shrink the tumor and improve the chance of successful surgery.
Jette, Brussels CapitalAges 18 years+ - NCT05916755Recruiting
Testing tumor clues that predict response to immunotherapy
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
BarcelonaAges 18 years+ - NCT05918302RecruitingPhase 3
Compare radiotherapy versus everolimus for lung and thymus tumors
This study compares two treatment options for somatostatin receptor–positive neuroendocrine tumors from the lung or thymus: radiotherapy versus everolimus. It aims to see which treatment works better and how safe each option is for people whose disease has progressed within the last year.
Edegem, EdegemAges 18 years+ - NCT05927818Recruiting
Test a sentinel lymph node biopsy in early ovarian cancer
This trial studies whether taking a sample from the sentinel lymph node during surgery can help with staging early ovarian cancer. It may help doctors find spread to lymph nodes more accurately while limiting unnecessary lymph node removal in some cases.
Istanbul, TurkeyAges 18–90 - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05933889Recruiting
Study of robotic throat surgery for early oropharyngeal cancer
This study looks at how well different robotic surgery approaches work for people with early oropharyngeal squamous cell carcinoma (throat cancer). You may be asked for consent for extra tissue and imaging analysis to help researchers understand patterns related to outcomes.
LondonAges 18 years+ - NCT05937620Recruiting
Mapping ovarian cancer sentinel nodes with two injected dyes
This study checks whether doctors can find the first lymph node(s) where ovarian cancer may spread using two dyes (a radioactive tracer and a green dye). It may help surgeons do more precise staging and treatment planning.
Barcelona, CataloniaAges 18 years+ - NCT05938322Recruiting
Ketogenic diet during pelvic cancer radiation treatment
This trial studies whether a very low-carbohydrate (ketogenic) diet can be followed safely while you receive neoadjuvant radiation for locally advanced rectal cancer. It may help researchers understand effects related to nutrition and treatment tolerance during radiation.
RomeAges 18–75 - NCT05952453RecruitingPhase 2
New ovarian cancer treatment with chemo plus maintenance medicines
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT05952947RecruitingPhase 1
Study drug for HPV18-positive solid tumors with a specific immune marker
This Phase 1 trial tests HRYZ-T101 injection for people whose solid cancer is HPV18-positive and who have the HLA-DRB1*0901 immune marker. It is meant for people whose cancer has returned or spread and who have few or no effective treatment options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05955196Recruiting
Immune therapy trial for colon cancer using CD47 blockers
This trial studies an immune-based treatment that targets CD47 to help your immune system fight colon cancer. It may help by changing the “immune environment” around the tumor so it can be more effective, and it is aimed at people with colon cancer that is advanced, recurring, or needing surgery.
MarseilleAges 18 years+ - NCT05957250Recruiting
PET scan study to better image pancreatic and bile duct cancer
This study uses a special PET scan drug (Ga-FAPI-46) to create clearer pictures of pancreatic and bile duct cancers. It may help doctors decide on the best next steps—especially before surgery—by checking tumor size and looking for spread.
Amsterdam, North HollandAges 18 years+ - NCT05962541RecruitingPhase 4
Using bladder scans to plan repeat surgery for bladder cancer
This trial checks whether a bladder scan and score (VI-RADS from MRI) can help doctors choose the right way to do a second look surgery for non-muscle-invasive bladder cancer. The goal is to reduce the chance of needing extra (“secondary”) resections while still catching important disease early.
Rome, LazioAges 18 years+ - NCT05965479RecruitingPhase 2
Blood test to guide extra stomach or esophagus cancer treatment
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Guildford, SurreyAges 18 years+ - NCT05967910Recruiting
How stress affects immunotherapy for esophageal cancer
This study looks at whether chronic stress changes how well immunotherapy (ICI therapy) works in people with esophageal cancer. It may help doctors understand who benefits most from treatment and how stress could affect outcomes.
Changsha, HunanAges 18–75 - NCT05968677Recruiting
Amino acids and flavonoids to reduce chemotherapy side effects
This trial tests whether a specific nutrition supplement (amino acids and flavonoids) can lessen chemotherapy side effects, support nutrition, and improve quality of life in people with non-metastatic breast cancer. It focuses on women who are receiving certain chemotherapy medicines and can eat by mouth and attend regular visits.
PaviaAges 50–70 - NCT05969496RecruitingPhase 2
Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Aurora, ColoradoAges 18 years+ - NCT05981326Recruiting
Computer model to predict chemo response in early breast cancer
This study looks at how well a computer model can predict if breast cancer will completely respond to chemotherapy before surgery. It is for people with early-stage breast cancer who are about to start neoadjuvant chemotherapy.
AngersAges 18 years+ - NCT05983276RecruitingPhase 2
Combination therapy for drug-resistant ovarian cancer
This trial tests a new two-drug combination (decitabine and selinexor) given with standard chemotherapy to see if it can reverse drug resistance in ovarian cancer that has come back or worsened after treatment.
Maywood, IllinoisAges 18 years+ - NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06008288RecruitingPhase 2
JAB-21822 for advanced pancreatic or other solid tumors with KRAS G12C
This study tests an experimental pill called JAB-21822 that targets a specific gene change (KRAS G12C) in advanced pancreatic cancer or other solid tumors. It's for people who have already tried standard chemotherapy and whose cancer has gotten worse or who couldn't handle the side effects.
Hefei, AnhuiAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,859 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.